<?xml version="1.0" encoding="UTF-8"?>
<abstract abstract-type="author-highlights" id="abs0015">
 <title>Highlights</title>
 <p>
  <list list-type="simple" id="ulist0010">
   <list-item id="u0010">
    <label>•</label>
    <p id="p0010">Interferon treatment has shown mixed efficiency against SARS-CoV and MERS-CoV.</p>
   </list-item>
   <list-item id="u0015">
    <label>•</label>
    <p id="p0015">SARS-CoV-2 is probably more sensitive to interferon than the other coronaviruses.</p>
   </list-item>
   <list-item id="u0020">
    <label>•</label>
    <p id="p0020">The IFNβ subtype appears to be the most suited for COVID-19 treatment.</p>
   </list-item>
   <list-item id="u0025">
    <label>•</label>
    <p id="p0025">Interferon treatment should be performed in the early stages of the infection.</p>
   </list-item>
   <list-item id="u0030">
    <label>•</label>
    <p id="p0030">Investigation on interferon-based COVID-19 treatment is warranted.</p>
   </list-item>
  </list>
 </p>
</abstract>
